Clinical Trial Update: A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations [Phase 2]

View source ↗

Summary

Phase II study of crenolanib in relapsed/refractory FLT3-mutated acute myeloid leukemia completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies | Phase 2 | Status: COMPLETED | Results posted: 2023-11-30